Vera Therapeutics, Inc. Class A

Stage 4 · Declining · week 11

As of Oct 22, 2026, Vera Therapeutics is in Stage 4, the downtrend phase, now in week 11 (since Aug 10, 2026). It closed at $29.05, 47.8% below its 52-week high and below its 200-day average, which is falling.

$29.05

-5.99% today

$2.1B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VERA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 20w

S3 17w

S2 19w

S4 19w

S2 19w

S3 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 9w → S4 2w → S2 20w → S3 17w → S2 19w → S3 4w → S4 19w → S1 6w → S4 5w → S1 5w → S2 19w → S3 14w → S4 4w → S1 3w → S4 11w current

Total tracked: 165 weeks across 16 stage runs.

VERA among Biotechnology203rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…203	VERAVera Therapeutics, Inc. Class A	Stage 4 · wk 11	50	−12.1%

vs 52W High

-47.8%

$24.10 lo$55.67 hi

47.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-22.5%

200 DMA: $37.51 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.16x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-12.1%

-18.1%

-24.3%

YTD

-40.3%

-4.2%

Scan Membership

Breakout Watch

Latest: 2024-09-05

5 appearances in last 60 days. First seen: 2022-04-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 1.16x

2026-10-21S4

Wk 11 · Vol 0.77x

2026-10-20S4

Wk 11 · Vol 0.54x

2026-10-19S4

Wk 10 · Vol 0.58x

2026-10-16S4

Wk 10 · Vol 0.59x

2026-10-15S4

Wk 10 · Vol 0.68x

2026-10-14S4

Wk 10 · Vol 0.66x

2026-10-13S4

Wk 10 · Vol 1.31x

2026-10-12S4

Wk 9 · Vol 0.62x

2026-10-09S4

Wk 9 · Vol 0.43x

2026-10-08S4

Wk 9 · Vol 0.75x

2026-10-07S4

Wk 9 · Vol 1.43x

Moving averages & range

50 DMA

$32.18

200 DMA

$37.51

52W High

$55.67

52W Low

$24.10

5D Low

$27.88

Resistance levels (recent highs)

20d High

$32.54

60d High

$36.82

120d High

$43.15

250d High

$55.67

Next resistance

+12.0%

to 20d High

ROE

-91.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.1

Vera Therapeutics: quick answers

What stage is Vera Therapeutics in?

As of Oct 22, 2026, Vera Therapeutics (VERA) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 10, 2026 and is in week 11. What the four stages mean

Is Vera Therapeutics in an uptrend?

No. Vera Therapeutics is in a Stage 4 downtrend. It trades 22.5% below its 200-day average, which is falling.

How far is Vera Therapeutics from its 52-week high?

Vera Therapeutics closed at $29.05 on Oct 22, 2026, 47.8% below its 52-week high of $55.67. Its 52-week low is $24.10.

How has Vera Therapeutics performed over the past year?

As of Oct 22, 2026, Vera Therapeutics is down 4.2% over the past year and down 40.3% so far in 2026.

Which sector and industry is Vera Therapeutics in?

Vera Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.